Biogen Inc. (BIIB) Earnings Call Transcript & Summary
April 25, 2023
Earnings Call Speaker Segments
Chuck Triano
executiveThanks, Bettina. Good morning, everyone, and welcome to Biogen's first quarter 2023 earnings call. Before we get started, I'd ask all of you to visit the investor section of biogen.com, where you'll find the earnings release along with the related financial tables — that includes our GAAP financial measures and a reconciliation of GAAP to Non-GAAP financial measures that we'll be talking about today on this call. Our GAAP financials appear in tables one and two, and table four contains a reconciliation of our GAAP to Non-GAAP financial results; in our view, Non-GAAP financial results give a better picture of the ongoing economics of our business and show how we manage the business internally. We've also put slides up on our website that track with the discussion related to this call. I want to note that we'll be making forward-looking statements, which rest on our current expectations. Such statements carry certain risks and uncertainties, and our actual results could differ materially. For more detail, I'd encourage you to review the risk factors discussed in our SEC filings. Joining me on today's call are our President and Chief Executive Officer, Chris Viehbacher, Dr. Priya Singhal, Head of Development, and our CFO, Mike McDonnell. Chris, Priya, and Mike will each give opening comments, and after that we'll go to the Q&A session. So we can get through as many questions as possible, we kindly ask that you limit yourself to one question. I'll now hand the call over to Chris.
Christopher Viehbacher
executiveThanks, Chuck. Morning, everyone. First off, I want to welcome Chuck Triano, who's joining us as the new Head of Investor Relations. Chuck, it's great to have you with us. When we spoke on the previous call, we laid out five priorities for the business, and you can see them on the first slide. I believe we achieved a great deal of solid progress on all five during the first quarter. We keep pushing forward on the possible launches of Leqembi for Alzheimer's disease and zuranolone for both MDD and PPD. I'll get into that on the following slide, since in certain respects it's genuinely a top-tier priority. Moving on to our next topic—improving how R&D manages risk and gets work done—Priya is going to take you through the steps we're taking on that front, and she'll give you a closer view of it. On the cost side, let me add a few points. To start, I'd like to note that the prior initiative targeting $1 billion in cost reductions has delivered strong results. That $1 billion is fully locked in, and we've finished that program. For the last few months, I've been getting a better sense of how things work here, collaborating with our top executives and thinking through the way we function across all levels of the business, particularly globally, regionally, and within each affiliate. We've noted before that our cost structure exceeds what's typical for companies in our space. So we've kicked off a new initiative designed to bring our operations and spending in line with the revenue we anticipate, while continuing to allocate enough money for the launches ahead. We refer to this initiative internally as Fit for Growth. The main thing we're trying to accomplish here is striking a balance. On one side, there's the chance to grow profitably by putting money into our product launches and the R&D projects we've marked as priorities. On the other side, we're working to trim the cost base and get it closer to where our competitors sit. This isn't just about cutting expenses in some simple way. Really, what we're doing amounts to rebuilding the company from the ground up. Take those two launches — early on, they'll each zero in on different geographies; zuranolone won't be available outside the U.S. for a few years. In the near term within the U.S., zuranolone is unmistakably at the top of the list. When it comes to markets beyond America, our initial priority is clearly going to be getting Leqembi off the ground. We need to protect the strengths this company already has — the things that have been delivering results. At the same time, we can't forget our position at the front of the multiple sclerosis field. Many people rely on the treatments we make, so the doctors caring for them must have everything they need to make informed decisions. Our aim is to find the right middle ground: channeling money into areas where we can grow, without pulling support from the MS franchise we've built over the years. We're doing this in a bottom-up, methodical way, and it may mean a significantly different operating model for us. For 45 years we've been in multiple sclerosis with a narrow set of products. True, at one time we had some hemophilia products, and of course we have Spinraza. Because of that, we carried a tremendous amount of centralized cost. At this point we're examining how to move far more of our resources and focus nearer to the customer. This is a redesign effort, and it's intended to last; we do see a chance to lower cost, but what we're really pursuing is something more transformational that positions the company for growth. We'll have more to share on that in Q2. Another key focus for us is how we handle the base business. There are two forces shaping things at the company right now. In MS, we're the leader, but competitors are increasingly pressuring that segment. At the same time, Leqembi and zuranolone give us chances to grow. When it comes to the base business, the challenge is figuring out how to operate it for maximum profitability. The Court of Justice of the European Union issued a favorable decision for us concerning Tecfidera's regulatory data and marketing protection, and that represented a significant strengthening of our intellectual property and exclusivity rights. In our view, this secures marketing protection through at least February of next year, and we plan to enforce that protection, even though it will take a while for the market to stabilize. On a different note, we keep defending the Tecfidera patent that runs through 2028 in Europe. At the same time, we want to get as much profit as possible out of the MS business. Until now, we were trying to protect revenue no matter what it cost. What we're after now is a more balanced strategy — figuring out where the MS opportunities sit, where we own intellectual property, where promotion still moves the needle — and align our spending accordingly, while maybe testing cheaper ways to market the products. We're confident Spinraza can return to growth, and things in the market appear to be leveling off. Not every patient can use gene therapy, and the oral option only goes so far—plenty of people with SMA still get no help from any available treatment. During our previous quarterly update, we mentioned that a formal review is in progress to weigh strategic choices regarding the biosimilars unit. That unit is performing well, and once Humira biosimilars enter the market in particular, I see an opportunity for the healthcare system to capture substantial savings that could offset the cost of innovation; we need to weigh how best to operate this business and determine the right kind of owner. Regarding growth through outside means, we tend to look at it from two angles. First, how do we make the company a bit more balanced around its pipeline? It's been heavily focused on neuroscience. As I've said before, since MS is essentially an autoimmune condition, I think we could move into immunology; through Spinraza, I think we've gained experience in rare diseases, and tofersen will strengthen that. And naturally, with zuranolone, we're in neuropsychiatry. These give us chances to consider how we build out some of those franchises. Second, I did mention this pattern of the MS franchise slipping a bit while new growth arrives; we might turn to external growth as a means of ensuring that shift goes as smoothly as possible when it comes to results. I'm happy to report that Adam Keeney has been named our head of corporate development. Adam brings more than 20 years of experience, not only in business development but also in R&D and strategy, spanning both large pharma and serving as the CEO of a biotech, so I think he carries an entrepreneurial spirit that will be most welcome at Biogen.
Christopher Viehbacher
executiveLeqembi and zuranolone, we definitely view as big revenue drivers, but as I mentioned, we want to keep exploring business development to fuel the growth path and broaden our portfolio. Next slide, please. We truly have an opportunity unlike any we've had before; right now there's a PDUFA date for tofersen; July brings a PDUFA date for Leqembi, and August brings one for zuranolone. I struggle to name another large biopharma company with so many important new products ready to launch. That's an enormous opportunity. Like I said before, we need to consider what capabilities that requires. These will span different therapeutic areas. Clearly, Leqembi is somewhat closer to our existing business since it remains with the neurologist, though a tremendous amount of market development lies ahead there. Naturally, zuranolone moves us into a very different space and a very different set of prescribing physicians. Our milestones are being hit. We got accelerated approval in the U.S. in January; we submitted for traditional approval in the U.S.; on that same day within the E.U., Japan, Eisai began regulatory filing in China. Filing all those dossiers within such a window is genuinely remarkable. I must congratulate our Eisai colleagues for this work. Priority review has been granted for these filings in the U.S., Japan, and China. And of course, a key milestone is that the Veterans Health Administration has chosen to reimburse Leqembi. Now, Leqembi is set to become the first anti-amyloid antibody to gain traditional approval globally, hopefully in July. As we've noted, this launch isn't simple; it's a complicated diagnosis requiring PET scans, lumbar puncture to confirm amyloid. Specialists are already stretched thin, plus MRI imaging, biweekly infusion. We recognize capacity may be a problem at first. CMS reimbursement will be the following big milestone, and we anticipate an answer once the product gets full approval as expected, after the July PDUFA date. More crucially, though, we're examining ways to relieve those bottlenecks right now. Yes, CMS matters, but both companies are already considering what can be done to simplify things for patients and actually lower cost. Eisai and Biogen are working on maintenance dosing and a subQ formulation. Blood-based diagnostics, as I've mentioned previously, will truly transform this field. Over time, we believe capacity will grow to match demand. On reimbursement, this is a significant question. The Veterans Association certainly helps. I'd simply note that versus what ADUHELM encountered, we're receiving far more backing from Congress. The American Academy of Neurology has expressed support in writing, and I understand many patient advocacy groups are working hard to make sure patients can access this vital therapy. Under the agreement, Eisai handles the CMS interaction, and we're optimistic that the CMS ruling will lead to wide coverage. Let me spend a few minutes on zuranolone. In my view, zuranolone remains an asset in our portfolio that gets too little credit. Sadly, many people deal with depression, and it's a sizable market. Quite a few older therapies are on the market, obviously. Those treatments' biggest drawbacks are their adverse effects and how long patients must wait before they help. zuranolone may act within three days, and the launch will look unlike others since this is a therapy that delivers results in 14 days. The closest comparison I can identify is Zithromax. We recognize that some education will be required. Doctors are accustomed to chronic treatment approaches. Even as we launch, we'll need to consider metrics differently. Typically, in a launch, one thing you watch is the point when NRx becomes TRx. That won't happen here. This product won't generate TRxs. I believe physician behavior will shift in these ways; this amounts to a paradigm shift, and as we know, a paradigm shift isn't always beneficial in pharmaceutical marketing. What truly motivates us is that this product genuinely changes patients' lives. This product delivers efficacy. It acts quickly. Consider the liberation of knowing you can cease zuranolone after 14 days. That, I believe, represents a tremendous opportunity. Let me wrap up with tofersen on this point. Clearly it isn't a large product, roughly 300 patients. Yet it's classic Biogen. There's a—we have a lengthy ALS history, many disappointments, but this organization can learn and adapt, and Biogen managed to collaborate with the scientific community to help establish neurofilament as a biomarker in neuromuscular disorders; that's enormously important since neurofilament will matter to numerous researchers studying ALS. I believe we have some revolutionary science here. This is an area where Biogen has shown the resilience to pursue substantial unmet need and has solved things in ways not everyone could. Next slide, please. As the slide shows, we have several milestones approaching. By our Q2 call, we anticipate being at a different stage with Leqembi. Ideally, the PDUFA date will be successfully behind us. Ideally, we'll have secured traditional approval along with wider CMS coverage in the U.S. Naturally, we'll share additional details regarding our Fit for Growth cost optimization program. By the close of this year, ideally, we'll have the first U.S. Getting the green light for Leqembi in Japan, and with any luck, we'll also have secured approval for zuranolone in both MDD and PPD, plus we'll have wrapped up a three-month DEA scheduling period and kicked off the launch. Looking a bit further out, by this same point next year, I believe there's a chance for us to expand Leqembi's global footprint through approvals in Europe and China. Naturally, we'll be taking the following steps toward reshaping the treatment paradigm in Alzheimer's disease, with a regulatory filing for Leqembi maintenance dosing that we expect to submit. We'd also anticipate a regulatory filing for subcutaneous dosing, which might make at-home administration possible; in closing, thanks to a mix of groundbreaking science, near-term commercial opportunities with high potential, and disciplined capital allocation, I think Biogen is going to be well-positioned for sustainable long-term growth. I'd like to now pass things over to Priya for an update on where we stand in R&D.
Priya Singhal
executiveThank you, Chris. During the quarter that just ended, we achieved meaningful momentum in moving forward our priority pipeline initiatives. As Chris mentioned moments ago, there is now a chance for us to bring three possible new medicines to market spanning four indications within this year, each addressing significant unmet medical needs, such as Alzheimer's disease, Major Depressive Disorder, postpartum depression, and SOD1-ALS; in addition, we keep assessing possible avenues for expanding zuranolone geographically and across indications while collaborating with our partner Sage to get ready for a possible U.S. rollout later in the year. I'll go over some major quarter highlights covering wider endeavors in Alzheimer's disease, the tofersen effort in SOD1-ALS, and the strides we're taking to rebalance risk and boost efficiency within the R&D pipeline. Now I'd like to discuss findings from further analyses that Eisai has recently shared or released, aligning with the dedication of both firms to openness. To start, on the topic of activities of daily living. A fresh examination of ADCS-MCI-ADL that was unveiled at ADPD during the previous month indicated that every single component of this measure supported Leqembi at 18 months when set against placebo. That encompasses things such as the capacity to prepare food or attend scheduled engagements. This finding likewise echoes the Clarity AD trial result on the CDR-Sum of Boxes, in which Leqembi therapy decelerated worsening throughout all six separate domains at 18 months relative to placebo. Furthermore, data from Clarity AD indicate that at 18 months, Leqembi therapy brought about a 50% smaller decrease from the starting point on instruments created to gauge quality of life and lessen the strain on care partners when compared with placebo. Also, an updated review of ARIA from the Clarity AD trial was shared, aiming to assess ARIA occurrence among participants given Leqembi who were taking antiplatelet or anticoagulant medications versus those given Leqembi who were on neither. The findings were positive, revealing that ARIA rates were comparable between the two sets of patients. Beyond the information shared at ADPD, freshly released analyses from the Leqembi phase II trial bolster the observation that although plaque levels start to creep back gradually once treatment stops, other biomarkers tied to AD pathology, like the plasma Abeta 42/40 ratio, rebuild rapidly. We think these results lend further weight to the possible advantage of ongoing Leqembi therapy once plaques are cleared. Expanding on earlier efforts, Eisai released a new evaluation of the long-term health consequences linked to Leqembi therapy. The revised analyses brought in information from the phase III Clarity AD trial, swapping out the earlier modeling that relied on phase II b results. The phase III data evaluation, matching the earlier phase IIb analysis, demonstrated that Leqembi produced a postponement of roughly 2 to 3 years in the average time until advancement to mild, moderate, and severe AD dementia compared with standard care by itself. We think these outcomes add to and strengthen the considerable evidence base amassed for Leqembi. Biogen remains dedicated to capitalizing on its extensive know-how and background in Alzheimer's disease by pushing forward a top-tier Alzheimer's pipeline that spans various therapeutic approaches and molecular targets. That takes in a focus on tau. The neurofibrillary tangles found inside cells, a hallmark pathology of Alzheimer's, consist of tau protein that has become hyperphosphorylated. Amyloid plaques are seen accumulating in the brain years ahead of cognitive symptom onset, but tau tangles correlate more tightly with loss of neurons and the emergence of clinical symptoms. To tackle tau pathology, we are moving forward with BIIB080, an antisense oligonucleotide directed at tau mRNA, with the goal of lowering every form of tau protein. It's worth noting this differs greatly from the strategy of using a tau-directed antibody, which is thought to hit only extracellular tau. We felt positive about what we've seen so far with this ASO-based approach. You can see that in the phase Ib results for BIIB080 in Alzheimer's disease, which were shared last month at ADPD and appeared in Nature Medicine, going live online yesterday. Those phase IB findings are shown on this slide. Overall, BIIB080 was tolerated well. Adverse events were mostly mild or moderate, with headache, back pain, and post-lumbar puncture syndrome being the ones reported most often. Across the multiple ascending dose and long-term extension periods, we observed a time- and dose-dependent decrease in CSF total and phospho-tau. In the MAD phase of the trial, total tau continued to fall 16 weeks following the final dose, among participants in both the high-dose every-4-weeks arm and the every-12-weeks arm, and a 50% drop from baseline was observed. Using tau PET imaging, we detected an impact on neurofibrillary tangles starting as early as week 25 in every brain region that was evaluated. By the conclusion of the open label extension, at 100 weeks, lessening of tau burden was evident in every treatment group. BIIB080 is the first study to demonstrate a tau PET decrease of this size across brain regions. These initial findings gave us reason for optimism, so enrollment continues in the phase II CELIA trial of BIIB080 for early Alzheimer's disease, where we're testing a range of dosing schedules, among them administration once every 12 weeks and once every 24 weeks. An FDA advisory committee convened last month to examine the tofersen data in SOD1-ALS. All members of that committee were in agreement that a decrease in plasma Neurofilament light is reasonably likely to serve as a predictor of clinical benefit for tofersen in treating SOD1-ALS; they likewise came to a shared conclusion that the benefit risk profile looked favorable. As Chris noted, Biogen has invested years of work alongside the scientific community to define neurofilament as a marker of axonal injury and neurodegeneration. The advisory committee's decision represents a major step forward for this area, in our view. We also think what's happened here sheds light on our other ALS efforts, such as BIIB105 and the antisense oligonucleotide aimed at ataxin-2, both of which could offer therapeutic benefit to a wider group of ALS patients. The goal behind BIIB105 is to bring down levels of the ataxin-2 protein, which we suspect will in turn cut back the harmful TDP-43 clusters seen in practically every person with ALS. Findings from preclinical work back this up: lowering ataxin-2 changed both survival and function in a mouse model of TDP-43 ALS. We expect to have results from the phase I-phase II study of BIIB105 in ALS early next year. Our R&D prioritization work keeps moving forward, aimed at maximizing what our pipeline can offer; that means putting money into places where our confidence in the disease biology runs deep. Additional data generation for Leqembi and zuranolone remains something we're investing in, and we stay committed to running three pivotal clinical trials — BIIB080 and BIIB105 among them, plus litifilimab for lupus. Beyond that, we chose to opt in to the Denali Antibody Transport Vehicle-Abeta program. Through ATV-Abeta, our goal is raising Abeta antibody exposure in the brain safely. That could lead to better plaque clearance and/or a reduced rate of ARIA. Meanwhile, we're pulling back on certain programs after weighing development, regulatory, and commercialization hurdles together. Among recent changes: we opted to end our work on developing BIIB093 programs for large hemispheric infarction and brain contusion, citing operational difficulties and strategic factors; we chose to hold off starting the phase IIb trial of BIIB131 in acute ischemic stroke while we reconsider whether that trial is needed; BIIB132 in spinocerebellar ataxia type 3 was discontinued; as announced earlier, our gene therapy investment was refocused; we'll keep seeking advanced technology for safely delivering such therapies to the proper targets within the body, which we see as among the most crucial scientific and technical hurdles facing this modality right now; and we had also said previously that we left ophthalmology research, intending to shift resources toward areas with what we judge to be a higher likelihood of success. This process will keep evolving, with scientific priorities and spending adjusted dynamically according to continuous assessments of success probability; we look to wrap up our first major review by mid-year. To close, Biogen achieved a great deal last quarter, and we think that underscores how our R&D team can seize upon and bring forward breakthrough science as we chase new treatments for patients. Given key assets spanning Alzheimer's disease, depression, ALS, and lupus, we're confident the Biogen pipeline can drive meaningful growth across the medium and long term. At this point, I'll hand the call to Mike for the financial results.
Michael McDonnell
executiveThanks, Priya. Morning, everyone. I'll walk through a few highlights from our financial results for Q1. Just a reminder that every comparison I mention is against the first quarter of 2022. First quarter total revenue came in at $2.5 billion, which represents a 3% decline at actual currency and was flat when measured at constant currency. Non-GAAP diluted EPS for Q1 was $3.40, down 6%. Turning to MS, total product revenue reached $1.1 billion, falling 19% at actual currency and 17% at constant currency. Let me offer a few observations on MS for the quarter. Within the U.S., we kept seeing pressure from Tecfidera generics, shrinking interferons, and competitive dynamics affecting TYSABRI. As we mentioned on our prior call, the first quarter tends to be seasonally softer for our U.S. MS business, reflecting elevated discounts and allowances along with certain channel dynamics. On that channel front, the drop in channel inventory came in larger than we had anticipated, contributing a few percentage points to the global decline overall. Our read is that this probably ties to tighter working capital management among wholesalers and specialty pharmacies given the rising interest rate environment. Beyond that, VUMERITY faces both pricing pressure and a shrinking oral segment of the U.S. market. Keep in mind that during last year's Q1, VUMERITY saw a favorable Medicaid-related sales adjustment, which further affects the year-over-year comparison. Turning to Europe, as you're aware, we got a favorable ruling regarding Tecfidera regulatory data and marketing protection in the EU. Our guidance had already assumed this; we hold the view that Tecfidera deserves regulatory marketing protection in the EU through at least February of 2024, and we're working to enforce that protection. I'd also note that we anticipated it would take time after the decision for all generic products to leave the market, and we expect that exit to speed up in the near term. On a separate note, we keep enforcing our patent, which runs through 2028. Looking at the rest of the year, we do anticipate a slower year-over-year rate of decline than what Q1 showed. We've taken certain actions aimed at improving the underlying revenue trajectory for our MS portfolio in the second half, including for VUMERITY in the U.S., and we continue monitoring the underlying MS market dynamics closely. Shifting to SMA, global SPINRAZA revenue was $443 million, a decline of 6% in actual currency and 2% at constant currency. In the U.S., SPINRAZA revenue fell 10%, driven by fewer new patient starts and certain channel dynamics relative to the first quarter of last year. That said, we do keep seeing what we consider signs of stabilization in our patient base. Beyond America, SPINRAZA's sales fell 4% in actual currencies while rising 2% when currency effects are stripped out, as rivals ate into results but shipment scheduling in some markets made up for it. Biosimilars brought in $192 million — down 1% using actual rates, up 4% on a constant-currency basis — thanks to greater volumes following the BYOOVIZ rollout, though European anti-TNF pricing pressure kept eating into that. Alzheimer's disease revenue, covering ADUHELM plus the Leqembi partnership, worked out to an $18 million drag on overall revenue. Keep in mind, from this quarter onward, our portion of Leqembi's U.S. commercial spend gets booked inside revenue, which explains the negative figure this quarter. We anticipate this line staying negative through 2023, since Leqembi commercialization costs will ramp over the year and should outpace early revenue. Anti-CD20 revenue overall came to $399 million, unchanged. OCREVUS royalties grew 12%, partly canceled out by a 25% drop in our Rituxan profit-share revenue amid biosimilar competition. That same anti-CD20 line carried a $10 million operating loss tied to LUNSUMIO. Worth noting, LUNSUMIO's R&D costs also sit within the anti-CD20 revenue line. Also important: starting in Q2, our pre-tax profit share on Rituxan, GAZYVA, and LUNSUMIO drops to 35% from 37.5%, reflecting sales targets tied to our Genentech contract. Contract manufacturing, royalty, and other revenue reached $319 million, lifted by production scheduling for certain contract manufacturing batches, Leqembi among them. That line swings around quarter to quarter, and we don't see this contract manufacturing level persisting through the rest of 2023. A few Q1 expense points: Non-GAAP cost of sales hit $663 million, 27% of revenue, which includes $45 million in idle capacity charges Eisai no longer covers. Q1 brought cost-of-sales pressure from product mix; higher contract manufacturing revenue carries steeper cost of sales, and Leqembi manufacturing revenue comes at minimal gross margin. For the rest of the year, we still expect cost of sales as a share of revenue above the 22.4% recorded for full-year 2022, mostly from product mix and idle capacity charges. Non-GAAP R&D for Q1 was $571 million versus $552 million a year earlier. Non-GAAP SG&A came in at $603 million against $635 million in Q1 of 2022. The reduction we saw in Non-GAAP SG&A expense came mainly from our cost savings initiatives, and it's worth noting those gains were partly offset by money we put into backing new product launches plus $31 million tied to ending the co-promotion agreement with Eisai covering Biogen's MS products in Japan; our expectation remains that operating expenses during the second half of 2023 will come in below what we saw in the first half. As Chris said, beyond the $1 billion cost savings initiative we announced earlier, we've kicked off our Fit for Growth program, which is meant to bring our cost base in line with anticipated revenue while we keep putting money into our growth opportunities. On 2023 expenses, we anticipate this program will have a modest effect, with a more meaningful effect arriving in 2024 and beyond. There will be more for us to share regarding this during our second quarter earnings call. Turning to our balance sheet, the quarter closed with $6 billion in cash and marketable securities, $6.3 billion in debt, and net debt of roughly $300 million. After the quarter ended, we collected approximately $830 million from selling our equity stake in Samsung Bioepis, and that figure isn't reflected in these cash numbers. This payment represents the second one tied to this transaction, which closed around this time last year, and a third payment of approximately $438 million is what we're expecting in April of 2024; during the first quarter, cash flow from operations came to $455 million. CapEx totaled $67 million. Free cash flow reached $389 million. All told, we continue to sit in a very strong financial position, holding substantial cash and financial capacity to put toward growing the business over time. Now let me move to financial guidance for full year 2023; we are reaffirming our full year guidance of a full year 2023 revenue decline in the mid-single-digit % range as compared to 2022 reported results and full year 2023 Non-GAAP diluted earnings per share of between $15 and $16. For other important guidance assumptions, I'd point you to our press release; to wrap up, Biogen kept making strong progress against our business priorities during the first quarter. Our focus stays on three potential launches in 2023, while we remain diligent about prioritizing our R&D pipeline, optimizing our operating model, and also evaluating external opportunities. Executing on these priorities should, we expect, put us in a good position to return Biogen to sustainable growth and create long-term value for our shareholders. With that, we will now open the call for questions.
Phil Nadeau
analystMorning, and thanks for taking our question. We'd like to ask about Leqembi reimbursement. Once full approval comes through, what does Biogen expect on the reimbursement front — coverage with evidence development, or something different? And second, when do you figure that will become clear? CMS has hinted that coverage gets revised the same day approval happens. Will that be the last word, or could there be more revisions down the road? Thank you.
Michael McDonnell
executiveChris, are you with us? Would you like to kick things off?
Christopher Viehbacher
executiveI'm hoping my mute is off now. Appreciate it, Phil. As far as CMS goes, there isn't much fresh information to share. According to CMS, once full approval is granted, they intend to ensure the product gets broad access. Whether a registry will be required, which kind of registry it would be, and whether that registry would have a cap — none of that has been settled yet. What's genuinely heartening is the substantial backing we're witnessing, along with pressure on CMS to provide reimbursement. The American Academy of Neurology, as I mentioned before, has declared its strong support. Keep in mind that back when Aduhelm was the issue, they leaned toward CMS's stance — so this represents a shift. The number of members of Congress who've sent letters to CMS is more than double what it was for Aduhelm. Some of you, I know, have been watching the budget talks in Washington and in Congress, which also include a push for CMS to make this product accessible. Our belief remains that the product will become available; our hope is that a registry won't be part of it. A registry isn't truly necessary, and we fail to see any reason this product shouldn't be reimbursed under Medicare just like any other. Realistically, nothing is likely to emerge until the PDUFA date has passed.
Paul Matteis
analystThanks a lot for taking my question. I was hoping to dig a bit deeper into external investments and how they tie into reshaping your pipeline. Chris, you've historically laid out rare disease, psychiatry and immunology. It seems that if you're going to lower the risk profile of your R&D strategy, then immunology and rare would lean more toward the developmental side, while for a psychiatry asset, you'd be looking for something either clinically de-risked or commercial. Is that the correct way to frame it? What's your appetite right now for doing deals before building everything up internally? Thank you.
Christopher Viehbacher
executiveThanks, Paul. I believe you've got that right. I mean, you could definitely consider some tuck-in acquisitions on the rare side. As I mentioned earlier, we've appointed Adam as Head of Corporate Development of Business Development. I think another important hire will be a new Head of Research, and my hope is to have that individual in place no later than the end of the summer; that individual, together with Priya and Adam, will really be the three people I'll be working alongside to think through things certainly from a licensing standpoint. When it comes to more transactions, I think we'd lean more toward finding something that generates revenue in the near term. If you look at Biogen, you know, really starting from 2025 onwards, I think the company has the ability to grow quite significantly. You know, over the next couple of years, that's where we are in this, you know, the tide going out on MS and the tide coming in on new products; we obviously have a lever with cost that we can pull, but external growth could also help us handle that transition period.
Geoff Meacham
analystHello, everyone. I really appreciate you taking the question. Chris or Priya, regarding BIIB080, plenty of tau candidates have disappointed, as you know, when tested alone in studies. Your team, however, is positioned unlike others to evaluate tau together with Leqembi. What I'd like to know is what results from phase II would be required, in your view, to move a combination forward? And from a strategic standpoint, where would that rank among your priorities? Thanks.
Christopher Viehbacher
executivePriya?
Priya Singhal
executiveYeah. Thanks, Geoff. That's an excellent question. Let me take a step back and note that, as everyone knows, Alzheimer's is an extremely complicated illness involving numerous biological pathways and intricate pathophysiology. We consider ourselves trailblazers in this area, and we've had success showing that Abeta plaques play a central role; at this point we've changed direction toward examining tau. As you're aware, we gained considerable knowledge regarding extracellular tau. That effort actually failed since BIIB092, which is gosuranemab, did not perform. Our current emphasis is truly on reducing all post-translational isoforms of tau. That is the goal of BIIB080. As we've communicated, the sample sizes in that phase Ib trial are clearly limited — the study that appeared online in a publication yesterday in Nature Medicine — yet the results are quite promising, since we observed roughly a 50% decrease in total tau along with a reduction that persisted after dosing; that's highly encouraging. When we consider leadership in Alzheimer's and think about numerous treatments, the first thing we must evaluate is how tau knockdown translates into clinical outcomes, and how much reduction is needed. If you examine mouse models — transgenic mouse models for tau — you actually find that around 50% can indeed rescue neuronal cell loss and memory. That's encouraging, though we require additional data from phase II. That's precisely our approach. In the end, I believe we firmly hold that this will be a multi-modality space, and patients will likely require more than a single therapy. Whether that means combination, or which — you'd have to establish whether it's synergistic or possibly additive — that's still to be determined. I think we'll allow the data to guide us on a lot of these questions. We're examining all of this extremely carefully. At present, our focus is tau knockdown, all isoforms, plus our phase I asset, BIIB113, which is investigating the prevention of tau aggregation. That's where we're directing our efforts.
Christopher Viehbacher
executiveIf I may add something there, Priya. As you know, Priya pointed out that after going through our pipeline, certain programs have been moved down our priority list. The goal there isn't simply cutting expenses. The real purpose is directing our resources toward the assets we view as having the greatest promise. After we announced those results in Sweden and the article ran in Nature, BIIB080 has drawn considerable interest, especially among people in neurology. This is an asset we genuinely intend to concentrate on; in fact, additional resources have already been assigned so that this program can move faster. Like Priya mentioned, this represents one of the earliest examples of what establishing a leadership position in Alzheimer's actually involves, rather than merely bringing a single product to market in that area. As you know, the majority of complex diseases ultimately wind up being treated with combinations, and, as you know, there's a reasonable chance that will hold true for Alzheimer's too. Regarding your point, I believe Biogen occupies a fairly strong position on that front, and we are definitely seeing interest from outside parties in this program as well.
Salveen Richter
analystMorning, and thanks for taking my question. Regarding Leqembi, could you walk us through your approach on the infrastructure side, especially infusion centers and testing, following a possible full approval and presuming CMS provides broad coverage?
Christopher Viehbacher
executiveSure, and thanks for asking. One of the more fascinating aspects is that the companies really did run a launch planning effort around Aduhelm and even funded a study to review and grasp what could be taken from that experience. There's a tremendous amount of the chicken and egg problem at play here. Before you have an approved therapy plus reimbursement, investment in other areas frequently falls short. Take blood-based diagnostics as an illustration. They exist, yet no market exists for a blood-based diagnostic before you truly have an approved drug and a treatment. That same dynamic applies to funding for infusion capacity, PET scans, lumbar punctures, and even neurology capacity. What we're definitely observing is far greater interest. Plenty of parties want to put money into some of this infrastructure. At this moment, the world is nearly at the point where, well, CMS approval really is the starting gate. Another lesson we picked up was that you want to flex your commercial investment in line with how well the system can actually serve patients. I believe one change we would make, and indeed are making, is that back then Biogen built up an enormous commercial machine ahead of reimbursement and ahead of some of that expansion. In our work with Eisai, we're being far more judicious, asking, okay, let's ensure we're present, we're educating physicians, we're considering who the right patient is for this, and coordinating with the various centers so we know which ones can see patients and handle them under this, this complex treatment paradigm; it will grow, and I think some of that growth already happened around the time of Aduhelm. I do think that, well, we'll see; we'll gain a clearer picture of where things are headed once CMS's reimbursement is confirmed.
Umer Raffat
analystHello everyone, good morning, and thank you for letting me ask a question. I was hoping to gain a bit more clarity regarding that -$19 million figure tied to the collaboration profit share on Lecanemab. More specifically, could you provide any detail at all about what end user revenues might look like, given the -$38 million for the franchise in 1Q? Even if it amounts to only a fraction of a million dollars, that would still be extremely useful to know. In addition, has Eisai shared with you where things stand, or what percentage of the commercial build-out is already reflected in that 1Q number, or is it not? As you can imagine, many investors are worried about how much SG&A they might be able to bill into this collaboration, particularly given certain concerns about the strained relationship from the past, and so on. Thank you so much.
Christopher Viehbacher
executiveAppreciate that, Umar. Mike, how about you handle the first portion of what was asked, and then I'll cover what we're spending on commercial infrastructure?
Michael McDonnell
executiveAbsolutely. Umer, the item you're asking about, as I'm sure you're aware, is essentially the net of whatever revenue there is and commercial spend, split in half. On the revenue figure itself, we aren't going to share a specific number. What I can tell you is that some revenue came in during the quarter. It was minimal. Most patients taking the drug are paying cash. As you know, reimbursement isn't in place yet. I'd say the true contest, if you will, really begins once reimbursement exists, assuming approval comes through and we reach that stage. Yes, revenue was minimal. Most of that line was cost halved, and I'll hand it to Chris to talk about the ramp going forward.
Christopher Viehbacher
executiveRight. Thanks, Mike. Regarding the relationship, I was in Japan the previous week, and I had dinner with Eisai's CEO, plus I believe our perspective is that the partnership and the relationship are truly functioning fairly well globally. As I mentioned before and have stated many times, this isn't a reach and frequency launch. Let's avoid thinking about the idea that we simply send reps out and then that will have some direct effect on sales. There's a great deal of education certainly being carried out. In reality, Eisai already has reps in the field within the U.S. We at Biogen will probably bring on reps at some future point, maybe as soon as next year, after the reimbursement situation is understood and capacity grows. Like I said, one lesson we needed to learn is you don't want to get ahead of that; this initial launch period will really be one constrained by capacity. So there's a tremendous amount of work partnering with the neurology community, teaching how to diagnose a patient, the entire practice process of when you obtain the PET scan or the lumbar puncture, how to arrange the MRIs, securing reimbursement, comprehending where infusion centers are located. It's a fairly high touch, high touch sell, along with customer relations at the beginning. As I said, there is an initial investment. A 2nd wave of investment will come once the CMS decision is known, and then likely a 3rd wave of investment as capacity builds and patient numbers rise.
Alice Nettleton
analystHello, and thanks for letting us ask something. Alice Nettleton here, filling in for Tim Anderson. It's about Alzheimer's. We'd like to know what Biogen assumes regarding how Lilly's donanemab profile will compare with Leqembi. Looking at earlier data, one might conclude it's less safe while delivering roughly equivalent efficacy. Does Biogen consider that the most probable result? Thanks.
Christopher Viehbacher
executiveYeah, appreciate the question. Honestly, that isn't really the lens we use. The Clarity study, I'd say, shifted everything. If you rewind to 2 years back, or 3 years back, plenty of people in neurology still questioned whether the amyloid beta hypothesis truly stands up. A massive argument has existed among those specialists over whether that target is legitimate. Clarity, in my view, genuinely begins to settle that argument. These trials ran across, in Clarity's situation, a timeframe of 18 months. What we're actually observing is that the landscape has progressed; across those 18 months, yes, we achieved a dramatic reduction in plaque, and we do see an advantage in the form of slower cognitive decline. That isn't the endpoint, though. Most likely, the way things are developing, at some stage you'll get a phase where plaque gets cleared. So what comes next once plaque is gone? Should treatment stop, plaque will return. Most likely there will be a maintenance phase. That's another reason the subQ formulation matters. As everyone knows, MCI isn't genuinely early stage Alzheimer's. Once MCI appears, once symptoms appear, you likely already carry a maximum plaque load. There are likely individuals listening on this call who, at this very moment, are building up plaque in their brains without realizing it. By the time a particular quantity of plaque has built up, a particular amount of neuronal death has already occurred. Currently, we lack the knowledge to bring neurons back. There will also be, as blood diagnostics advance, and even a signed Biogen study ahead examining earlier patients, as one neurologist put it, we no longer view this as a four-year to eight-year disease; instead we view it across a 25 year period. Regarding donanemab, fine, they... In certain respects, positive data from them would be welcome, since it would further strengthen the amyloid, the beta amyloid hypothesis. And moreover, we've consistently observed in new markets that when more players exist, those markets grow faster. This donanemab notion of merely treating until some specified plaque reduction is reached, most neurologists I speak with no longer think that aligns with how we now approach Alzheimer's treatment. My guess is it will exist, though I doubt it gets adopted the way folks imagined back when that research was first designed. Like I mentioned, having additional companies in this space would be a positive thing, but when it comes to going head-to-head against donanemab, that's not something that worries us much.
Michael Yee
analystHello, and thanks. Good morning, everyone. Our question concerns what you anticipate following reimbursement with regard to the Leqembi rollout. We realize you're unable to share an excessive amount of detail, yet how ought we to approach that relative to consensus projections of $40 million-$45 million and $400 for the coming year? Perhaps you can assist us in calibrating how this begins, whether a bolus exists or whether a queue of patients stands ready, and regarding the way we ought to model the forthcoming four to six quarters. Thanks.
Christopher Viehbacher
executiveYes. I would like to provide you with additional guidance on this matter. As I frequently put it, my confidence regarding the three-year to five-year outlook is quite strong. Even for us, modeling the coming 18 months proves somewhat harder. There is, you know, tremendous interest. Some queuing will likely occur. How rapidly the system can flex will remain an open question. My approach to thinking about it, and how I view Biogen, is that zuranolone, I believe, is genuinely a product capable of contributing more swiftly to our sales growth during 2024. I do believe that one, yes, represents a paradigm shift, yet patient benefit is evident, and none of the infrastructure difficulties must be surmounted. For me, I look more toward zuranolone's impact in the next year. By the close of this year, once we observe the initial takeoff during the first six months, after CMS releases its reimbursement, we'll be able to offer a considerably clearer picture.
Robyn Karnauskas
analystHello, and thank you for allowing me to ask. Everything shared today has been quite useful. Regarding a registry, if one exists, could you explain how significant an obstacle it could become? In what way would it be funded? And please assist us, when that decision comes out, in grasping what the difficulties might be, or whether it might actually be less of a burden than people expect. Thank you.
Christopher Viehbacher
executiveCertainly, some registry designs are not especially burdensome, though the specifics will determine everything. That is precisely why, once more, we would want CMS to cover this product the same way it covers any other. Considering that diverse and underserved patients within the healthcare system endure Alzheimer's disproportionately, making things harder for those patients through a registry requirement would strike us as profoundly unjust toward them. Still, we will have to see. We believe the evidence from Clarity is incredibly unambiguous. The advantages extend well beyond what appears in the CDR-Sum of Boxes, as Priya mentioned. Looking at those activities of daily life, assessed by individuals who spend every single day alongside these patients, you find six measures, and every one of them on its own reaches statistical significance. To me, that indicates... Compared with placebo. To me, this indicates that those who interact with these patients daily recognize the value of this novel medicine and treatment. I would say the data are persuasive, and we are hoping no registry is required, and should one be required, that it creates the least possible burden for patients to act and for their caregivers to navigate.
Marc Goodman
analystGood morning, Priya. Could you perhaps walk us through what these halted programs have in common? I realize there are a handful in stroke, plus some additional ones, but where's the overlap? It caught my attention that stroke is sitting in phase III, so should we read that as a sign other late-stage assets might also be cut from the pipeline? From a philosophy standpoint, thinking big picture, how did you approach these calls? Thanks.
Priya Singhal
executiveOf course. Our approach to these calls has been to examine each program very thoroughly — multiple times, in fact — asking ourselves what choices exist, what operational, strategic, and regulatory hurdles we face, and equally what openings there are. It's genuinely a holistic assessment of where we think our resources could be put to better use on other programs in our current portfolio. That, I'd say, is the thread connecting every decision you're hearing about from us today. Our view is that our time is better spent somewhere else. That said, as you mentioned, BIIB093 sits in phase III. What the result might be is something I'm not in a position to address, but at this point we are in fact ending its development.
Terence Flynn
analystGreat. Thanks a lot for answering that. Perhaps a follow-up for Chris regarding zuranolone. I believe in your prepared remarks, you mentioned this asset is underestimated, and from what you said earlier, it sounds like you potentially see some upside to the numbers. Should we interpret that as the main point — that you believe there's upside to outer-year consensus estimates for that asset? Any update at all on the commercial footprint regarding the build and what it might eventually look like over time? Thank you.
Christopher Viehbacher
executiveThanks, Marc. When I look at this, it's quite interesting, and I genuinely pay close attention to what analysts and investors have to say, and I definitely recognize that from our vantage point as a company, the opportunity we see for zuranolone is much bigger than what the street is projecting. I've tried to figure out what's behind that disconnect. I honestly haven't come up with a solid explanation, except that in my view the investment community has been heavily concentrated on things such as rare diseases and oncology; in those areas we have very distinct biomarkers. We have extremely targeted therapies. Precision medicine plays a major role in both of those spaces; now we're shifting back to primary care. We're shifting back to a condition that is... Figuring out what's actually going on is much tougher, especially when you consider various indications. Take bipolar depression, major depressive disorder, and general anxiety disorder — you'll frequently find all of these showing up in one person. In fact, psychiatrists will tell you, if you ask them directly, that this is genuinely personalized medicine. Those specialists aren't as influenced by guidelines or by what KOLs have to say; they focus more on grasping what each individual patient requires. That's a departure from what people have grown accustomed to examining. It's entirely clinical data and so forth. I believe that's true from a commercial model standpoint. What's proving a bit harder for the market to grasp is the way a physician goes about deciding what's right for their patient. Here's what I can share: we've held conversations with a large number of patients, and we've even brought patients in front of our global executive committee. Physicians have also addressed our global executive committee. This way of doing things differs greatly from what our company has historically been accustomed to when it comes to working with neurologists. Another thing that stands out clearly is the substantial unmet need out there. Patients move from one therapy to another. Those therapies leave them less than fully satisfied. Stigma weighs heavily in this area, and continuing to take medicine just makes that stigma stronger. So I've spoken with doctors who tell me, "People show up in the ER and there's nothing we can do for them. No beds are open, so what we do is give an SSRI or a comparable drug and simply hope someone monitors that patient over the next 6 weeks." The fact that a drug is capable of working quickly is significant. Being caught in a depressive episode is one of the most difficult experiences a person can face. And hearing patients recount how suddenly their entire life turns upside down — one woman we cared for had dealt with this on and off for close to 20 years. She's a mother of 3 children and grandmother to 5. Just days later, she was doing better. She earned her certification to teach fitness classes. Now she is pursuing a pilot's license. Honestly, that kind of change is transformative for a huge number of the people we treat. That is the standard I personally rely on. Another lens on this, Marc, is what happens when you hire sales reps. We are filling 27 positions — the initial first-line manager spots within our field force that are under consideration. More than 4,000 people applied for those jobs. These candidates currently work at strong organizations and back strong medicines. I can recall the Aubagio launch, back when nobody expected much from Aubagio. Wow, once we assembled that field force, we managed to bring on a terrific group. Sales reps investigate on their own, you know, and they typically want to be involved with drugs they consider meaningful. I'm seeing plenty of signals suggesting this will connect with patients. It definitely is connecting with the sales staff — the individuals we're bringing aboard. I'm also hearing that from numerous key opinion leaders. That part is tough to argue with. The single area where I'd flag some caution is this: it's unmistakably a paradigm shift. As I like to put it, swapping out a spouse you've had for 20 years can be simpler than altering how a physician writes prescriptions. That's because doctors lean heavily on what they've seen in practice. My view is there's a significant unmet need in this space. I genuinely believe the potential here is enormous. This product has me extremely enthusiastic. If I simply pay attention to patients — and I often say this — whenever an unmet need exists and I can spot a difference from what's already available, the drug is going to succeed.
Jay Olson
analystThanks for the update, and congratulations on all the progress. Could you discuss what the ideal capital structure looks like for Biogen, and how much additional debt might you be able to take on to pursue business development? Thanks for taking the question.
Christopher Viehbacher
executiveMike, do you want to take that one?
Michael McDonnell
executiveSure, I'll handle that one. Thanks for asking, Jay. So, at the close of the quarter, we had roughly $6 billion in cash. Like we said, after the quarter ended, we got that payment from Samsung of about $813 million. That brings us to nearly $7 billion in cash on hand. Our EBITDA is around $3 billion. On a gross debt basis, we're at about two turns. Clearly, net debt is near zero. If you pro forma for the Samsung payment, it's actually negative. There's additional capacity. Just to illustrate, adding a turn of leverage would put you at 3x gross. Net would still be quite modest, and if you combine that with the cash, that gets you to north of, or in the vicinity of, roughly $10 billion of dry powder, if you will. I'm not saying we'd take on more debt just for the sake of it. For the right opportunity, the right BD opportunity, and so on, I believe our capital structure gives us plenty of flexibility. And with $830 million, that's a solid position.
Chuck Triano
executiveWe're aware that everyone has additional calls on their schedule. Operator, could we please take one more question?
Colin Bristow
analystMorning, and thanks for fitting me in. Chuck, welcome aboard as well — great to be collaborating with you once more. Regarding subcut Leqembi, what exactly has the FDA told you needs to happen for approval? Could you describe how big a role the subcut version plays in the commercial picture? What share of patients could it reach that the infusion can't? That's the commercial sub-question. The VHA is leaving out APOE4 homozygotes. Could you address the danger you perceive, whether in labeling or commercially, upon full approval as access widens? Thank you.
Robyn Karnauskas
analystAll right. Thanks, Colin. I'll take the first one. Sure. Let me begin with the subcutaneous formulation. That plan remains on schedule.
Priya Singhal
executivePer Eisai, the filing was expected by Q1 2024. To give context, the assessment happens within the phase III open label extension through a subcutaneous sub-study. Eisai further noted they had talked over with FDA and other regulators what's needed to move ahead with that filing, produce the data, and then file subsequently; in their view, the current approach does permit evaluation of PK/PD plus safety, which is what would be necessary. Now to the following point. What you raised, I believe, concerned the APOE4 homozygote. Eisai shared some of that data at ADPD and commented on the matter too. In their view, the dataset was actually fairly limited. The count of APOE4 homozygotes was very small. Their position is that the broader conclusions remain unchanged concerning Clarity AD and, you know, confidence in those data. Another thing worth remembering is that in fact a lot of the secondary endpoints went in Leqembi's favor. There might be a factor of placebo declining less within this comparator group, and they raised that point too; as for the commercial angle on subcutaneous, I'll hand it over to Chris or Mike.
Michael McDonnell
executiveYeah, I mean, I think on, you know...
Christopher Viehbacher
executiveThanks, Priya.
Michael McDonnell
executiveGo ahead, Mike.
Christopher Viehbacher
executiveGo ahead, Chris.
Michael McDonnell
executiveYeah. No, what I was about to say is that from a commercial standpoint for subcutaneous, this is going to be kind of revolutionary, and then we'll just have to watch how it unfolds. As time goes on, you know, Alzheimer's patients together with the people caring for them are, you know, perhaps shifting toward more of a maintenance phase for their treatment. This might be something quite valuable, especially for patients who have some distance to cover to reach an infusion center, so they could give it to themselves at home. We believe it could hold a great deal of promise. There will be more to share about that down the road. We should be hearing additional details within the next nine months or so, and, you know, we think it might serve as a significant differentiator should everything come together.
Christopher Viehbacher
executiveI mean, just for what.
Michael McDonnell
executiveThanks, everybody.
Christopher Viehbacher
executiveOh, I just wanted to jump in there, Chuck — at this point, we really don't view the biweekly infusion as a constraint on that infusion. As Mike mentioned, it does matter when we consider that, if we can secure a maintenance indication along with blood diagnostics, you know, how long someone stays on the drug could potentially shift down the road, and in that kind of situation, the subQ would definitely have an impact. Over to you, Chuck.
Michael McDonnell
executiveYeah, thanks, Chris. We appreciate everyone tuning in today. If you have further questions, feel free to reach out to the investor relations team, and that wraps up this call.
Operator
operatorThis concludes today's call. Thank you for your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.